Fig. 1
From: METTL3 drives NSCLC metastasis by enhancing CYP19A1 translation and oestrogen synthesis
METTL3 is highly expressed in primary lesions and metastatic lymph nodes of NSCLC, indicating a poor prognosis. (A) The CPTAC database indicates high expression of the METTL3 protein in lung adenocarcinoma tissues. (B) The TCGA database indicates high expression of METTL3 mRNA in NSCLC. (C) Western blot analysis indicates high expression of METTL3 in tumour tissues from 8 NSCLC patients. The right panel displays the quantification results of the left panel. (D) IHC staining of a tissue microarray from 96 patients indicates high expression of METTL3 in primary lesions and metastatic lymph nodes of NSCLC. (E) Quantification results of IHC staining in tissue microarrays. (F) METTL3 expression of primary tumours in N0 stage patients is significantly lower than that in N1-N3 stage patients. (G) DIA-MS results from late-stage NSCLC revealed that METTL3 expression of primary tumours in M0 stage patients is significantly lower than that in M1 stage patients. (H) Survival analysis demonstrates the relationship between METTL3 expression in tissue microarrays and the prognosis of NSCLC patients, with high expression of METTL3 suggesting poor prognosis